Loading clinical trials...

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation

NCT01918683•Abramson Cancer Center at Penn Medicine

View on ClinicalTrials.gov

Summary

This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm

Detailed Description

The purpose of this study is to determine whether the combination of stereotatic body radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective "bridging therapy" for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient capable of giving informed consent
•Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed for orthotopic liver transplantation at the participating institution
•Age \> 18 years old
•Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
•Childs' Class A or B7
•Eastern Clinical Oncology Group performance status 0 or 1

Exclusion Criteria

•Prior radiotherapy to the upper abdomen or radioembolization of the liver
•Prior TACE to the target lesion, RFA, or liver transplant
•Active GI bleed within 2 weeks of study enrollment
•Active GI ulcer disease within 4 weeks of study enrollment
•Ascites refractory to medical therapy
•Contraindication to receiving radiotherapy or TACE
•Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
•Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable to undergo follow-up imaging or SBRT treatment planning)
•Women who are pregnant
•Participation in another concurrent treatment protocol

Locations (3)

Loyola University Medical Center

Maywood, Illinois, United States

Oregon Health & Science University

Portland, Oregon, United States

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

July 1, 2013

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2027

Last Updated

January 29, 2026

Enrollment

ESTIMATED participants

Conditions

Hepatocellular Carcinoma

Interventions

TACE transarterial chemoembolization

RADIATION

stereotatic body radiotherapy (SBRT)

RADIATION

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

Inclusion Criteria

Exclusion Criteria

Early Detection of Liver Cancer by QUS

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)